Medison pharma announces agreement with regeneron pharmaceuticals to commercialize libtayo® (cemiplimab) in multiple countries

Libtayo (cemiplimab) is a leading pd-1 inhibitor that has shown efficacy in the treatment of certain patients with cutaneous squamous cell carcinoma, advanced basal cell carcinoma, advanced non-small cell lung cancer and advanced cervical cancer, and is approved by regulatory authorities in more than two dozen countries for various indications medison and regeneron will work together to continue patient access to this important therapy in select markets zug, switzerland , jan. 8, 2024 /prnewswire/ -- medison pharma ("medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, announced today their exclusive multi-national agreement with regeneron ireland dac, a wholly owned subsidiary of regeneron pharmaceuticals, inc. (nasdaq: regn), a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases, to commercialize libtayo® (cemiplimab), a fully human monoclonal antibody targeting the immune checkpoint receptor pd-1 on t cells, in select european markets and additional markets around the world.   libtayo was invented in laboratories at regeneron, which acquired exclusive worldwide development, commercialization, and manufacturing rights to the medicine from sanofi in july 2022.
REGN Ratings Summary
REGN Quant Ranking